Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.71 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2639283 | 0.88 | HDAC1 (0.67) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL29221845 | 0.87 | HDAC6 (0.73) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL30858828 | 0.87 | HDAC6 (0.73) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL14461305 | 0.86 | HDAC1 (0.72) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL4929814 | 0.86 | HDAC1 (0.71) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL4866671 | 0.86 | HDAC1 (0.71) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL2641717 | 0.86 | HDAC1 (0.81) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL30858826 | 0.83 | HDAC1 (0.81) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL20509078 | 0.83 | HDAC1 (0.76) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL13991492 | 0.83 | HDAC1 (0.72) | HDAC1HDAC2HDAC6HDAC3HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | claimed |
| JP-4603265-B2 | — | — | 2010-12-22 | — | — | JP | claimed |
| US-6995143-B2 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-02-07 | — | — | US | claimed |
| EP-1478653-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2004-11-24 | — | — | EP | claimed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | claimed |
| WO-2003072588-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2003-09-04 | — | — | WO | claimed |
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-6995143-B2 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-02-07 | — | — | US | disclosed |
| EP-1478653-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2004-11-24 | — | — | EP | disclosed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | disclosed |
| WO-2003072588-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212011-A1 | Macrolides with antibacterial activity | MRPL21, RPS21, MRPS18A | HDAC1 134/4885HDAC2 596/4885HDAC6 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.